Enhanced RNA Vaccination with FlashRNA®
FlashRNA® enhances RNA-based vaccination by combining high-efficiency, multiplexed RNA delivery with a strong safety profile and scalable manufacturing. It allows to quickly and transiently co-deliver multiple distinct RNAs, as antigen(s), immunomodulators, or adjuvants in a single vaccine dose, potentially enhancing immune responses or enabling multi-antigen vaccines.
Efficient induction of neutralizing antibody response has been proven after either intradermal or intramuscular vaccination in mice, requiring widely lower doses compared to a standard RNA-based vaccine.
Vaccination with FlashRNA® induces a specific neutralizing antibody response using several hundred times lower doses compared to a commercial COVID-19 vaccine
The efficacy of FlashRNA® as a vaccine was evaluated through testing its ability to stimulate an antibody response against the Spike protein from the SARS-CoV-2 virus, compared to similar data from literature. In this model, FlashRNA® was administrated intradermally, and the level of neutralizing antibodies was assessed. The data show a very efficient induction of neutralizing antibodies at very low doses, compared to a commercial COVID-19 vaccine, attesting that the administration of multiple low doses of FlashRNA® results in the efficient delivery of the antigen to the immune system, which is then able to mediate a specific antibody response.
FlashRNA®-mediated antigen expression induces an antibody response after repeated intramuscular injections
FlashRNA® ability to stimulate an antibody response following repeated intramuscular administration of an mRNA construct expressing a specific antigen was assessed through quantification of the level of secreted antibodies after each administration.
FAQ
What are the differences between FlashRNA® and LNPs?
LNPs are synthetic, whereas FlashRNA® is biologically derived. All FlashRNA® components are synthesized in human producer cells. So, FlashRNA® encapsulates biological RNAs of human origin and not synthetic, in vitro-transcribed RNA, like LNPs. Moreover, FlashRNA® is a complex, multi-layered structure allowing protection of the packaged RNAs, thanks to a protein capsid surrounded by a biological lipid membrane. Thus, as a bioengineered virus-like particle (VLP), FlashRNA® has a lower intrinsic immunogenicity and highly efficient entry into a broad range of cell types, compared to LNPs.
What is the nature of RNA packaged in FlashRNA® particles?
RNA incorporated within FlashRNA® particles is transcribed endogenously in producer cells during particle assembly, thereby constituting biological RNA rather than synthetic, in vitro–transcribed RNA. As a consequence, these RNAs possess the full repertoire of natural post-transcriptional modifications introduced by human cellular machinery, reflecting authentic modification patterns found in physiologically expressed RNA species.
Which administration routes are possible?
A variety of routes of administration have been assessed in vivo. These include intravenous (IV), intramuscular (IM), intradermal (I.D.), subcutaneous (SC), and stereotactic administration, as well as intra-articular (in the joint) administration.
Is FlashRNA® redosable?
Yes, FlashRNA® has been tested in vivo, with up to three successive injections, without generating toxicity or a non-specific immune response.
Is FlashRNA® already used in therapy?
Yes, FlashRNA® has been produced as a Drug Product, to be used for a First-in-Human phase 1/2 clinical trial in 2025 (LymphARN trial, to treat secondary lymphedema).
Contact us
Do you have a project in mind? We’d love to hear from you!
